Novel Tubeimoside I liposomal drug delivery system in combination with gemcitabine for the treatment of pancreatic cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Novel Tubeimoside I liposomal drug delivery system in combination with gemcitabine for the treatment of pancreatic cancer

Published:2024-09-03 Issue: Volume: Page:1-17
ISSN:1743-5889
Container-title:Nanomedicine
language:en
Short-container-title:Nanomedicine

Author:

Li Shuhui¹^ORCID,Liu Yuansheng²^ORCID,Sui Xiaojun³⁴,Zhuo Yuzhen³,Siqi He⁴,Sijia Zhang⁴^ORCID,Hui Zhang³,Dihua Li³,Dapeng Zhang³,Lei Yang³^ORCID

Affiliation:

1. School of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China

2. Department of Colorectal Surgery, Tianjin Union Medical Center, Tianjin, 300000, China

3. Tianjin Key Laboratory of Organ Injury and ITCWM Repair Associated with Acute Abdominal Diseases, Tianjin Nankai Hospital, Tianjin Medical University, Tianjin, 300100, China

4. Graduate School ofTianjin Medical University, Tianjin, 300270, China

Funder

Tianjin Key Medical Discipline Construction Project

Science Foundation of Tianjin Municipal Health Bureau

Tianjin Natural Science Foundation

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17435889.2024.2382076

Reference49 articles.

1. Burden of Pancreatic Cancer: From Epidemiology to Practice

2. Error in Box

3. Pancreatic ductal adenocarcinoma chemoresistance: from metabolism reprogramming to novel treatment

4. Fundamental insights and molecular interactions in pancreatic cancer: Pathways to therapeutic approaches

5. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP